Acceptability of cognitive remediation for schizophrenia: a systematic review and meta-analysis of randomized controlled trials

被引:46
|
作者
Vita, Antonio [1 ,2 ]
Barlati, Stefano [1 ,2 ]
Ceraso, Anna [1 ]
Deste, Giacomo [2 ]
Nibbio, Gabriele [1 ]
Wykes, Til [3 ,4 ]
机构
[1] Univ Brescia, Dept Clin & Expt Sci, Brescia, Italy
[2] ASST Spedali Civili Brescia, Dept Mental Hlth & Addict Serv, Brescia, Italy
[3] Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Psychol, London, England
[4] Maudsley Hosp & Inst Psychiat, South London & Maudsley NHS Fdn Trust, Denmark Hill, London, England
关键词
Acceptability; cognitive remediation; drop-out; meta-analysis; schizophrenia; systematic review; PSYCHOSOCIAL TREATMENT; TRAINING-PROGRAM; LOW-SUPPORT; THERAPY; ADHERENCE; EFFICACY; OUTCOMES; IMPACT; BLIND; RATES;
D O I
10.1017/S0033291722000319
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background Acceptability is an important factor for predicting intervention use and potential treatment outcomes in psychosocial interventions. Cognitive remediation (CR) improves cognition and functioning in people with a diagnosis of schizophrenia, but its acceptability, and the impact of participants and treatment characteristics, remain to be investigated. Few studies provide a direct measure of acceptability, but treatment drop-out rates are often available and represent a valid surrogate. Method The systematic search conducted for the most comprehensive CR outcomes database for schizophrenia was updated in December 2020. Eligible studies were randomized clinical trials comparing CR with any other control condition in patients diagnosed with schizophrenia spectrum disorders and that also reported drop-out in treatment and control arms separately. Acceptability was measured as odd-ratios (OR) of drop-out. Results Of 2119 identified reports, 151 studies, reporting 169 comparisons between CR and control interventions with 10 477 participants were included in the analyses. The overall rate of drop-out was 16.58% for CR programs and 15.21% for control conditions. In the meta-analysis, no difference emerged between CR interventions and controls [OR 1.10, 95% confidence interval (CI) 0.96-1.25, p = 0.177]. Factors improving acceptability were: inpatient only recruitment, participants with fewer years of education and lower premorbid IQ, the presence of all CR core elements, and the presence of techniques to transfer cognitive gains into real-world functioning. Conclusions CR for people diagnosed with schizophrenia is effective and has a good acceptability profile, similar to that of other evidence-based psychosocial interventions.
引用
收藏
页码:3661 / 3671
页数:11
相关论文
共 50 条
  • [31] Dopamine partial agonists and prodopaminergic drugs for schizophrenia: Systematic review and meta-analysis of randomized controlled trials
    Osugo, Martin
    Whitehurst, Thomas
    Shatalina, Ekaterina
    Townsend, Leigh
    O'Brien, Oisin
    Mak, Tsz Lun Allenis
    McCutcheon, Robert
    Howes, Oliver
    NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 2022, 135
  • [32] Efficacy and tolerability of aripiprazole once monthly for schizophrenia: a systematic review and meta-analysis of randomized controlled trials
    Oya, Kazuto
    Kishi, Taro
    Iwata, Nakao
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2015, 11 : 2299 - 2307
  • [33] Effects of psychological treatments on functioning in people with Schizophrenia: a systematic review and meta-analysis of randomized controlled trials
    Bighelli, Irene
    Wallis, Sofia
    Reitmeir, Cornelia
    Schwermann, Felicitas
    Salahuddin, Nurul Husna
    Leucht, Stefan
    EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, 2023, 273 (04) : 779 - 810
  • [34] CARDIOMETABOLIC RISKS OF BLONANSERIN AND PEROSPIRONE IN THE MANAGEMENT OF SCHIZOPHRENIA: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
    Kishi, Taro
    Matsuda, Yuki
    Iwata, Nakao
    SCHIZOPHRENIA RESEARCH, 2014, 153 : S191 - S191
  • [35] Cardiometabolic Risks of Blonanserin and Perospirone in the Management of Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Kishi, Taro
    Matsuda, Yuki
    Iwata, Nakao
    PLOS ONE, 2014, 9 (02):
  • [36] Prodopaminergic Drugs for Treating the Negative Symptoms of Schizophrenia Systematic Review and Meta-analysis of Randomized Controlled Trials
    Sabe, Michel
    Kirschner, Matthias
    Kaiser, Stefan
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2019, 39 (06) : 658 - 664
  • [37] HISTAMINE H2 BLOCKERS FOR SCHIZOPHRENIA: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
    Oya, Kazuto
    Kishi, Taro
    Iwata, Nakao
    SCHIZOPHRENIA RESEARCH, 2014, 153 : S276 - S276
  • [38] Hypnotherapy for insomnia: A systematic review and meta-analysis of randomized controlled trials
    Lam, Tak-Ho
    Chung, Ka-Fai
    Yeung, Wing-Fai
    Yee-Man, Branda
    Yung, Kam-Ping
    Ho-Yee, Tommy
    COMPLEMENTARY THERAPIES IN MEDICINE, 2015, 23 (05) : 719 - 732
  • [39] Acupuncture for chloasma: A systematic review and meta-analysis of randomized controlled trials
    Liang, Shuang
    Huang, Kai-Yu
    Xu, Yue-Ting
    Sun, Yi-Nong
    EUROPEAN JOURNAL OF INTEGRATIVE MEDICINE, 2017, 14 : 37 - 45
  • [40] Effectiveness of medication review: a systematic review and meta-analysis of randomized controlled trials
    Huiskes, Victor Johan Bernard
    Burger, David Marinus
    van den Ende, Cornelia Helena Maria
    van den Bemt, Bartholomeus Johannes Fredericus
    BMC FAMILY PRACTICE, 2017, 18